Subjects enrolled with biopsy confirmed NASH experienced clinically and statistically significant improvements in liver stiffness as measured by FibroScan, a non-invasive measure of liver fibrosis
Subjects with NASH experienced clinically and statistically significant improvements in alanine aminotransferase (ALT), a measure of liver cell inflammation, at both dose levels of AXA1125
Findings demonstrate improvement in hepatic fat as measured by MRI-PDFF
AXA1125 continues to demonstrate a safe and well tolerated profile
Axcella to host a conference call today at 8:00 a.m. ET; To register, click here
